BALVERSA (erdafitinib) Patient Assistance Program
Don’t let the high cost of brand specialty oral oncology therapy disrupt your treatment. We help eligible patients access Balversa (erdafitinib) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Balversa (erdafitinib) is FDA-approved for adults with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one prior line of systemic therapy.
- Without assistance, Balversa costs commonly run approximately $19,000–$23,000 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Balversa for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Balversa in the U.S. as of 2026. Other targeted therapy or immunotherapy options for advanced urothelial carcinoma include enfortumab vedotin (Padcev), sacituzumab govitecan (Trodelvy), pembrolizumab (Keytruda), atezolizumab (Tecentriq), nivolumab (Opdivo), avelumab (Bavencio), and chemotherapy.
What Is Balversa Prescription Assistance Program?
The Balversa Prescription Assistance Program is a manufacturer-sponsored initiative that provides Balversa at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for advanced urothelial carcinoma patients with FGFR3 alterations who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology coordination, FGFR3 genomic-testing documentation, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Balversa costs roughly $19,000–$23,000/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$22,000 | Save ~$21,930/mo |
| CVS Pharmacy | ~$23,000 | Save ~$22,930/mo |
| Walmart | ~$19,500 | Save ~$19,430/mo |
| Costco | ~$19,200 | Save ~$19,130/mo |
| Specialty Pharmacy | ~$20,000 | Save ~$19,930/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Balversa Prescription Program?
The Patient Assistance Program is free to apply for and provides Balversa at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Balversa:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
- Still $19,000–$23,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Balversa assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Balversa Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Balversa:
Balversa (erdafitinib) is a once-daily oral pan-fibroblast growth factor receptor (pan-FGFR) tyrosine kinase inhibitor used for advanced urothelial carcinoma with susceptible FGFR3 alterations. It targets a specific cancer-driving genetic alteration that is present in a subset of urothelial carcinoma patients.
How Balversa Works:
Erdafitinib is a pan-FGFR inhibitor that targets the ATP-binding sites of FGFR1 through FGFR4, effectively blocking the phosphorylation required for cell growth. It is specifically used for urothelial carcinomas that are “addicted” to FGFR3 signaling due to genetic mutations or fusions. By inhibiting these specific growth drivers, the drug induces tumor responses in patients identified through FDA-approved genomic testing. However, inhibiting these receptors can also lead to off-target effects like hyperphosphatemia and ocular changes.
Form and use:
Marketed as Balversa, this medication is taken orally as a single daily tablet, regardless of food intake. The standard starting dose is 8 mg, which may be increased to 9 mg after two to three weeks if the patient’s serum phosphate levels remain below a specific target. Ongoing use requires careful ocular monitoring and potential dose adjustments to manage adverse events or phosphate levels.
Generic availability:
As of 2026, there is no generic version of Balversa available in the United States. Other advanced treatment options include immunotherapies like pembrolizumab, antibody-drug conjugates like enfortumab vedotin, and traditional chemotherapy. The selection of these treatments is highly dependent on the patient’s prior clinical history, biomarker profiles, and specific FGFR3 status.
Warnings:
Balversa is associated with significant ocular disorders, such as central serous retinopathy, necessitating regular eye exams using OCT technology. It frequently causes hyperphosphatemia, which serves as a clinical marker for dose titration, and carries a warning for embryo-fetal toxicity. Other common side effects include stomatitis, hand-foot syndrome, dry skin, hyperglycemia, and elevated liver enzymes.
FAQ (Frequently Asked Questions)
How Much Does Balversa Cost Without Insurance?
Balversa costs approximately $19,000–$23,000 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Balversa at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Why Do I Need Genomic Testing Before Balversa?
Balversa only works in urothelial carcinoma patients whose tumors carry specific FGFR3 alterations (mutations or fusions). FDA-approved companion genomic testing identifies these patients. Without susceptible FGFR3 alterations, Balversa is not effective. Your oncologist orders the genomic test on tumor tissue (or sometimes blood) before starting therapy.
What Are The Most Common Side Effects?
Common side effects include high blood phosphorus levels (hyperphosphatemia — used to guide dose titration), oral mucositis, nail changes (separation, splitting), hand-foot syndrome (palmar-plantar erythrodysesthesia), dry mouth, dry skin, dry eyes, decreased appetite, and elevated liver enzymes. The eye effects (central serous retinopathy) require regular ophthalmologic monitoring.
Why Do I Need Eye Exams On Balversa?
Balversa can cause central serous retinopathy and retinal pigment epithelial detachment — fluid accumulation under the retina that can affect vision. Optical coherence tomography (OCT) and visual acuity should be checked at baseline, monthly for the first 4 months, every 3 months thereafter, and any time you have new vision symptoms. Tell your oncologist immediately about new vision changes.
Can I Get Balversa Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria
How Long Will I Be On Balversa?
Treatment continues as long as the disease is responding and the medication is well tolerated. Some patients continue Balversa for many months; others discontinue earlier due to disease progression or adverse events. Imaging is typically done every 6–12 weeks.
What If My Application Is Denied?
If denied, we explore alternatives — switching to other treatments for advanced urothelial carcinoma (enfortumab vedotin/Padcev, sacituzumab govitecan/Trodelvy, immunotherapy, chemotherapy), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Bladder Cancer Advocacy Network (BCAN), PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Balversa, our team may be able to help you access assistance programs designed to make brand specialty oral oncology therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.